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INTRODUCTION
Leukotrienes and other eicosanoids, resulting from 5-
lipoxygenase activity on arachidonic acid metabolism,
have been implicated in the pathogenesis of cerebral VSP
after SAH.
5-lipoxygenase activity enhanced after SAH. Significant
in the pathogenesis of cerebral VSP? Inhibitor should
ameliorate experimental VSP.
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INTRODUCTION
 The present study evaluates the potential therapeutic 
value of ABT-761, a selective 5-lipoxygenase inhibitor 
on cerebral vasospasm in an in vivo rabbit model of 
SAH.
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METHODS











SAH - 5ml autologous blood into the cisterna magna
Drug or placebo PO 30 minutes after hemorrhage and
repeated 24 hours later.
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METHODS
 48 hours after CSF was collected from the cisterna magna 
for ABT-761 concentration determination.
 Animals were sacrified, using the perfusion-fixation 
method. Basilar artery was removed.
 The cross-sectional areas of basilar artery histological 
sections were measured by an investigator blinded to the 
treatment groups of the individual samples.
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Statistical Analysis
 A Kruskal-Wallis one-way analysis of variance was
performed on the entire data set of morphometric
measurements. Pairwise multiple comparisons post-hoc
analysis was performed using the Bonferroni-Dunn
method.
 Partial correlation coefficients were performed on CSF
ABT-761 concentration values by treatment groups.
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RESULTS
In placebo-treated animals, the average luminal cross-
sectional area of the basilar artery was reduced by 68% after
SAH compared to controls (P<.0001).
After SAH the vasospastic response was attenuated in
animals treated with 20 and 30 mg/kg representing a 28% and
35% reduction respectively (P=.0011 and P=.0038).
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DISCUSSION
 The greater degree of variability in drug concentration 
among control animals may indicate a trend towards 
variable drug utilization in the SAH animals than in 
Control animals.
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DISCUSSION
 Vasospasm is a major complication after SAH
 Difficulties in prevention and treatment
 Pathogenesis still unclear, likely to be multifactorial, with
inflammatory processes involved
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DISCUSSION
Leukotrienes are inflammatory mediators with cerebral 
vasoconstrictor properties
Production is elevated in SAH
CSF levels correlate with vasospasm
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DISCUSSION
ABT-761 is a second-generation, potent and selective 
inhibitor of leukotriene formation both in vivo and in vitro
Able to prevent experimental VSP, by attenuating the 
vascular effects of the 5-lipoxygenase products of arachidonic 
acid metabolism
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CONCLUSION
Established the potential utility of a specific leukotriene 
inhibitor for the treatment of experimental VSP
Indirect evidence for a role of inflammation in the 
pathogenesis of cerebral vasospam
Primate studies are needed to clarify whether 5-
lipoxygenase inhibition has a potential role in the treatment of 
clinical cerebral vasospasm
